Board at their meeting held on 29.05.2025 interalia approved audited standalone and consolidated financial results for the quarter/year ended 31.03.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sunil Healthcare Ltd's Board, at its meeting on May 29, 2025, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. The statutory auditors, Singhi & Co., issued an unmodified (clean) opinion on both sets of results, as confirmed by the CFO's declaration. On a consolidated basis, the auditor's report explicitly references a net loss for the full year ended March 31, 2025, even though the standalone results show a net profit for the year. The Board has decided not to recommend any dividend for FY 2024-25. Additionally, the company appointed M/s. ATCS & Associates as Secretarial Auditor for five years (FY 2025-26 to FY 2029-30) and M/s. Agrawal S. Lal & Co. as Internal Auditors for FY 2025-26.
Shareholders will not receive any dividend for FY25, which is a negative signal for income-seeking investors. The consolidated net loss for the full year, despite a standalone profit, suggests losses at the foreign subsidiaries (Mexico and North America) weighed on group earnings — worth monitoring closely.